All In Biotech

Drug Trial Radar · NCT05543330

A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC

A Phase 1, Multicenter, Open-label, Dose-increasing Study to Evaluate the Safety, Tolerability, PK/PD and Preliminary Efficacy of M701, a Recombinant Epcam and CD3 Bispecific Antibody , in Patients With Malignant Pleural Effusions Caused by NSCLC

Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 116 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

116

Planned (sponsor's estimate)

Start

Sep 30, 2022

Primary completion

Sep 15, 2026

Study completion Dec 15, 2026

Sponsor

Lead sponsor
Wuhan YZY Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1/phase 2, multicenter, open-label study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of M701 in patients with treatment of malignant pleural effusions caused by NSCLC.

Conditions

  • Malignant Pleural Effusions
  • NSCLC Stage IV

Interventions

  • M701 pleural infusionDrug

    M701 pleural infusion on Days 1,4,7 and 10.

  • Pleural drainageProcedure

    Pleural effusion drainage via Ultra-sound guidance on Day 1.

  • Cisplatin pleural infusionDrug

    Cisplatin pleural infusion (30-50mg/m2) on Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicities (DLTs)Time frame: From the time of the first dose (Day 1) until the forth dosing (Day 28)
  2. Incidence of AEsTime frame: From the start of administration to the end of the study or 28 days after the administration is stopped
  3. Puncture-free survival (PuFS)Time frame: The time from removing the thoracic drainage tube after last intrapleural infusion to the time when re-drainage is required or death, assessed up to 12 months after enrollment or randomization.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.